ArticleJournal of fluorescence2026
Development of a Time-Resolved Fluorescence Immunoassay for BAFF and Its Preliminary Clinical Application in Patients with Lupus Nephritis.
Article in Journal of fluorescence, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
This study was designed to develop a time-resolved fluorescence immunoassay (TRFIA) for the detection of B-cell activating factor (BAFF) and to evaluate the preliminary clinical utility of serum BAFF measurement in patients with lupus nephritis (LN). A BAFF-TRFIA was established using 96-well microplates coated with anti-BAFF monoclonal antibodies, combined with anti-BAFF polyclonal antibodies and europium (Eu³⁺)-labeled goat anti-rabbit IgG as the detection antibody. Serum BAFF concentrations were measured in 46 patients with LN and 30 healthy controls to assess the clinical applicability of the assay. The developed BAFF-TRFIA demonstrated a sensitivity of 27.62 pg/mL and a linear detection range of 97.66-25,000 pg/mL. The intra-assay and inter-assay coefficients of variation ranged from 1.44% to 9.17% and from 2.34% to 11.93%, respectively, indicating acceptable assay precision. Serum BAFF concentrations exhibited substantial inter-individual variability in patients with LN. Compared with healthy controls, a broader distribution of BAFF concentrations and several markedly elevated values were observed in the LN group. Relatively higher BAFF concentrations were predominantly observed in patients with class III and class IV LN. In summary, a BAFF-TRFIA with a wide detection range was successfully developed based on a europium (Eu³⁺) chelate. This method enables the quantification of soluble BAFF in biological samples and has been successfully applied to the measurement of serum BAFF in patients with LN. The established assay provides a promising approach for the clinical evaluation of soluble BAFF.
Indexed as
Identifiers
42377648What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.